INKT   $0.72  0.0 Market Closed

Mink Therapeutics Inc
Last Events:

2023-08-09 Trend pattern changed from расходящийся клин с наклоном вверх to канал.

2023-08-09 Signal in Stochastic changed from bearish weakening to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-09 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-06 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: main and signal line crossing.

2023-08-05 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.

2023-08-05 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Trend Power changed from slow to .

2023-08-05 Trend changed from turning down to flat and down.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 8.00
Mean unverified/preliminary 8.00 / 8.00
Target Price Low / High 7.00 / 9.00
Median / STD DEV 8.00 / 1.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Buy Buy
rsi Sell ActivelyBuy ActivelyBuy
macd None None None
stoch None None None
ma20 Sell None None
ma50 None None None
ma100 Buy Buy Sell
Candlestick PatternOct. 23, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US6036931029
ceo Dr. Jennifer S. Buell Ph.D.
Website https://minktherapeutics.com
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.